Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. The company is headquartered in Melbourne, Victoria. The firm is focused on the development of two orally available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The firm is focused on Phase II trials of AMP945 in patients with pancreatic cancer and idiopathic pulmonary fibrosis. The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH). The company is also focused on a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
Amplia Therapeutics (ASX: ATX)
- Home
- Amplia Therapeutics (ASX: ATX)
Here are the latest articles on Amplia Therapeutics (ASX: ATX)
Amplia reports results from initial clinical trials of pancreatic cancer drug
March 27, 2024
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) is conducting a clinical trial—the ACCENT trial—for pancreatic cancer. The trial will test a new drug called narmafotinib in combination with standard chemotherapy. Narmafotinib targets a protein called FAK (Focal Adhesion Kinase), which is becoming a hot area of research in cancer treatment. Amplia’s drug aims to make
The ASX listed biotech companies making their mark in oncology
March 31, 2023
Balance sheets don’t tell the whole story. This is especially true for biotech companies where pre-revenue businesses can still be worth billions of dollars with the innovative medicines they are creating. On a macro level, biotech companies outperformed the S&P 500 and both pharmaceutical and medtech sectors in terms of total returns to shareholders over
Recent Articles
